News | April 25, 2026
Bayer’s comeback gains speed as CEO warns: “The Work Isn’t Complete. Yet"
The Pharmaceuticals portfolio and pipeline are more promising than perhaps ever before
The Pharmaceuticals portfolio and pipeline are more promising than perhaps ever before
Our company is prioritising deeper collaborations with CDMOs and biosimilar companies as part of its strategy to expand its footprint across India, Middle East, and Africa region
Deal includes 13 branded generic products across 55+ countries; acquisition expected to strengthen global anti-infective portfolio and expand regulated market presence
Growth was broad-based across segments
Angelique Kruif brings over 20 years of HR leadership built across a range of international organisations
The investment will bring in cutting-edge downstream fermentation technology, strengthening the company’s contract manufacturing capabilities for drug substances
The move reinforces Croda’s push to fuel growth through high-impact innovation across its Consumer Care portfolio
Neuland Laboratories reported an uptick in peptide-related engagements from Japanese companies, particularly at the preclinical and early clinical stages
Move comes amid rising regulatory pressures
The newly approved pill combines 100 mg of doravirine with 0.25 mg of islatravir
Subscribe To Our Newsletter & Stay Updated
